Ionis Pharmaceuticals 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Ionis reported strong second quarter 2026 financial results with revenues of $268 million and $514 million for the first half, representing 56% and 69% year-over-year growth, respectively.
- Product sales for commercial medicines increased, including $5 million in Q2 and $32 million in the first half from triangles, despite a strategic price reduction on April 1st.
- Don Zahra generated $26 million in Q2 and $42 million in the first half, with a 63% increase in Q2 sales compared to Q1.
- Research and development revenue was $149 million in Q2 and $288 million year-to-date, reflecting progress in partnered programs.
- Ionis achieved FDA approval of triangles for severe hypertriglyceridemia (StG), marking the first medicine to reduce triglycerides and risk of acute pancreatitis in adults with severe hypertriglyceridemia.
- The launch of triangles is off to an encouraging start with prescriptions received on day one and both 50 mg and 80 mg doses available within one week.
- Don Zahra continues to gain momentum in hereditary angioedema prophylaxis, capturing meaningful U.S. market share less than one year after launch.
- Ionis remains on track for the anticipated launch of Xeljanz for Alexander Disease later this year, with FDA priority review and an expanded access program underway.
- The phase three reveal study for Angelman syndrome completed enrollment, with data expected next year.
- Clinical development was initiated for ion 337 in Dravet syndrome, expanding the neurology pipeline to eight wholly owned medicines.
- Ionis and AstraZeneca reported that eplontersen did not meet the primary efficacy endpoint in the overall population in the cardio Transform phase three study for ATTR cardiomyopathy, though nominally significant results were seen in the monotherapy subgroup.
- Ionis ended Q2 with $2.1 billion in cash, cash equivalents, and short-term investments.
- Operating expenses increased due to commercialization and pipeline advancement costs, with 2026 operating expenses expected to rise in the low teens percentage range.
- Non-GAAP operating loss is projected between $425 million and $475 million for 2026, similar to 2025 after adjusting for a one-time license fee.
- Ionis projects 2026 full-year revenue between $875 million and $900 million, including $100 million to $110 million in triangles product sales and $110 million to $120 million in Don Zahra sales.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to Ionis second quarter 2026 financial results conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walk, Senior Vice President of Investor Relations, to lead off the call. Please go ahead. Thank you, Andrea.
Before we begin, I encourage everyone to go to the investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financials results better represent the economics of our business and how we manage our business. We've also posted slides on our website that accompany today's call. With me this morning are Brett Monia, Chief Executive Officer, Kyle Jenne, Chief Global Product Strategy Officer, Holly Kordasiewicz, Chief Development Officer, and Beth Hougan, Chief Financial Officer. Eugene Schneider, Chief Clinical Development Officer, and Eric Swasey, Executive Vice President of Research, will also join us for the Q&A portion of the call. I would like to draw your attention to slide three, which contains our forward-looking language statement.
During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail. With that, I'll turn the call over to Brett.
Thanks, Wade. Good morning, everyone, and thank you for joining us on today's call. Ionis enters the second half of 2026 well-positioned to achieve the strategic opportunities that lie ahead. We have the R&D engine, the pipeline, commercial capabilities, and financial discipline we need to execute on and achieve our goals. We are continuing to build momentum across our commercial medicines, and in parallel, we continue to strengthen and advance our wholly owned pipeline to deliver our next wave of important medicines. Last month, we achieved a landmark milestone with the approval of TRYNGOLZA as the first and only FDA-approved medicine to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, or sHTG. Although still early days, we are highly encouraged with our launch momentum to date. In fact, we began receiving prescriptions for TRYNGOLZA on the day of approval.
We are also pleased that both the 50 milligram and 80 milligram doses were in the channel within one week. Based on a strong profile and the enthusiasm we are seeing in prescribing, we are confident that TRYNGOLZA is well-positioned to help a large population of patients in need and become the first Ionis-owned multi-billion dollar medicine. DAWNZERA for hereditary angioedema also continues to gain momentum. We expect DAWNZERA to continue driving growth as it becomes more established in the HAE prophylactic treatment landscape. We also continue to advance our leadership in the development of breakthrough treatments for a wide range of neurological diseases. We remain on track for the anticipated launch of zilganersen coming up soon, which is positioned to be the first disease-modifying treatment for Alexander disease and the first independent launch from our neurological disease pipeline.
Following closely behind zilganersen is obudanersen, our medicine for Angelman syndrome, which completed an enrollment in the phase III REVEAL study last month, keeping it on track for data next year. Earlier this month, we also announced the initiation of clinical development for ION337 in Dravet syndrome, expanding our clinical stage neurology pipeline, which now includes eight medicines that are wholly owned. Complementing our wholly owned pipeline is our partnered pipeline, which includes medicines targeting both rare and highly prevalent diseases, providing significant additional value for Ionis. This includes bepirovirsen, our medicine for chronic hepatitis B. With a PDUFA target action date of October 26 and additional global filings under review, bepirovirsen is on track for a global launch this year, positioning it to be a first-in-class medicine for the millions of people around the world living with this disease.
Data from the phase III pelacarsen Lp(a) HORIZON study in patients with elevated Lp(a) and cardiovascular disease is also a key catalyst coming up in the second half of this year. We were disappointed with the outcome of the CARDIO-TTRansform phase III study for eplontersen in ATTR cardiomyopathy that we reported earlier this month. Although eplontersen demonstrated substantial and durable reductions in TTR, nominally significant results in the monotherapy subgroup and favorable safety, it did not meet the primary efficacy endpoint in the overall population. We and AstraZeneca continue to analyze the data and will present the results at ESC in August. Our strong commercial execution, continued pipeline progress, and our strong second quarter financial performance underscore the many opportunities we have to continue building substantial value. We remain on track to deliver on our 2026 financial guidance and achieve our goal of cash flow breakeven in 2028.
With that, I'll now turn the call over to Kyle, who will speak to the commercial execution of TRYNGOLZA and DAWNZERA and launch preparations for zilganersen. Ole will then discuss how we are advancing our pipeline, highlighting several important catalysts ahead. Beth will review our financial results and outlook. With that, I'll turn it over to Kyle.
Thank you, Brett. Our commercial momentum continues to build, positioning us to deliver even greater impact in the second half of the year and beyond. We are executing well against our commercial priorities, including strong progress on the TRYNGOLZA and DAWNZERA launches and preparation for the zilganersen launch. Beginning with TRYNGOLZA, demand continues to build in FCS, driven by an increasing number of patients initiating and remaining on treatment As expected, second quarter product sales reflected the reduced TRYNGOLZA wholesale acquisition cost that went into effect on April 1st.
We updated the price ahead of the anticipated SHTG approval to align with annual payer contracting cycles to accelerate access to TRYNGOLZA. Underlying demand in FCS remained strong, with the second quarter delivering the highest number of patient starts since launch began. Together with our commercial execution in FCS and early market access efforts, we've established a strong foundation for the next phase of TRYNGOLZA growth as we launch in the broader patient population. The recent approval of TRYNGOLZA for SHTG marked a defining moment for Ionis. Importantly, it expanded our opportunity to serve millions of people living with severely elevated triglycerides. We were particularly pleased with the TRYNGOLZA label, which includes prevention of acute pancreatitis in the indication statement.
The label is supported by the groundbreaking results from the phase III CORE and CORE2 studies, which further underscores the importance of preventing acute pancreatitis in people with SHTG. Building on this strong foundation, I'm happy to share that the SHTG launch is off to an encouraging start in the first few weeks. Thanks to the exceptional execution of our commercial team, we began receiving prescriptions on day one in both the 50 milligram and 80 milligram doses were in the channel within approximately one week. Since the approval, our team has already engaged with many of our top physician targets who care for the majority of high-risk patients. In addition, our omni-channel launch campaign has produced strong engagement, which is further helping to rapidly build awareness of SHTG, APOC3 biology, and TRYNGOLZA.
There are an estimated 3 million people in the U.S. with SHTG, including approximately 1 million people with high-risk SHTG who have triglycerides above 880 milligrams per deciliter, or triglycerides above 500 and a history of acute pancreatitis or other comorbidities. The risk of acute pancreatitis begins to increase at triglyceride levels above 500 and rises exponentially in people with triglycerides above 880. As the first to market therapy with a novel mechanism proven to reduce the risk of painful, costly, and potentially fatal acute pancreatitis attacks, TRYNGOLZA is well positioned to serve patients across both segments. The majority of high-risk SHTG patients are treated by approximately 20,000 cardiologists, endocrinologists, and lipidologists across the U.S., with additional patients treated by primary care physicians. Early in the launch, we are seeing prescriptions from all three specialties, in addition to a meaningful contribution from primary care physicians.
We've also seen physicians prescribe TRYNGOLZA to people with high-risk SHTG and those with TGs between 500 and 800 milligrams per deciliter with no history of acute pancreatitis. Physicians are prescribing both the 50 and 80 milligram doses, highlighting the importance of dosing flexibility, which enables treating physicians to tailor treatment to the individual needs of each patient. Importantly, we are executing on our market access strategy as planned. We have made good progress obtaining coverage for the broad population in patients with triglycerides above 500 milligrams per deciliter and across both commercial and government plans. Ultimately, we expect the SHTG market to comprise approximately 60% commercial and 40% government-covered patients. We also expect payer coverage to continue expanding through the remainder of this year and into next year as payers complete their reviews. We're also making progress in expanding access to TRYNGOLZA outside the U.S.
In the EU, Sobi is continuing to advance the launch in FCS, while also actively laying the groundwork for a strong launch in the broader SHTG indication anticipated next year. With this early SHTG launch momentum, TRYNGOLZA is on track to meet our full year 2026 revenue guidance and positioned to achieve our projections for more than $3 billion in peak annual revenue. The DAWNZERA launch also continued to gain momentum. In less than one year on the market, DAWNZERA has already captured a meaningful share of the U.S. HAE prophylaxis market, which is largely a switch market. This growth is driven by increasing adoption across all patient segments, including patients switching from existing prophylactic therapies, patients who were previously only using on-demand treatment, and treatment-naive patients.
Physicians and patients consistently provide positive feedback on DAWNZERA, highlighting DAWNZERA's strong efficacy and favorable safety profile, its differentiated RNA targeting mechanism, the positive switch data which HCPs describe as, quote, "differentiating and motivating," end quote, and DAWNZERA's patient-friendly profile that includes a self-administered auto-injector that can be stored at room temperature for up to six weeks. The base of repeat prescribers continues to grow. This is a key indicator that DAWNZERA is providing substantial benefit for patients and HCPs are having a positive experience prescribing it. Given that most patients on HAE prophylactic medicines are already established on existing therapies, continued penetration will take time. However, the launch fundamentals give us confidence that DAWNZERA will contribute meaningfully to our commercial revenue growth in 2026 and beyond. Outside the U.S., our partner, Otsuka, is making good progress with DAWNZERA in the launch in the EU.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
17 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
